Skip to content
September 21, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Kanker Payudara

Kanker Payudara

Primary Menu
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Watch
  • Home
  • Genomics and Precision Medicine
  • A New Era for Genomic Science: ASHG Announces Strategic Publishing Partnership with Oxford University Press
  • Genomics and Precision Medicine

A New Era for Genomic Science: ASHG Announces Strategic Publishing Partnership with Oxford University Press

Ali Ikhwan September 21, 2026 7 minutes read
a-new-era-for-genomic-science-ashg-announces-strategic-publishing-partnership-with-oxford-university-press-1

ROCKVILLE, MD — In a move set to reshape the landscape of genetic research dissemination, the American Society of Human Genetics (ASHG) has officially announced a landmark partnership with Oxford University Press (OUP). Beginning in January 2027, the world’s largest university press will assume responsibility for the production and dissemination of ASHG’s two prestigious scholarly publications: The American Journal of Human Genetics (AJHG) and the open-access journal Human Genetics and Genomics Advances (HGG Advances).

This strategic transition marks a significant milestone for the ASHG, which represents nearly 8,000 professionals globally, including researchers, clinicians, and educators. While the operational and logistical aspects of publishing will migrate to OUP, the Society has underscored its commitment to maintaining absolute editorial independence. ASHG will retain full control over peer review processes and editorial direction, ensuring that the journals continue to uphold the rigorous standards of scientific integrity that have defined the Society for over seven decades.


The Core Facts: A Strategic Alignment of Mission and Expertise

The transition is more than a change in vendor; it is a realignment of scientific outreach. The ASHG journals serve as the heartbeat of the human genetics community, documenting everything from fundamental discoveries in molecular biology to the clinical application of genomic medicine.

  • The Journals: AJHG, the Society’s flagship publication, has been a pillar of the field for over 75 years, chronicling the most significant breakthroughs in human genetics. HGG Advances serves as the Society’s rapid-publication, fully open-access platform, designed to provide a home for diverse research formats and findings that meet the Society’s high standards for reproducibility.
  • The Partnership: Oxford University Press brings a legacy of over 500 years of publishing expertise to the table. By leveraging OUP’s global distribution networks, digital infrastructure, and extensive experience in society-led publishing, ASHG aims to broaden the visibility of its authors’ work.
  • The Transition: The changeover will officially take effect on January 1, 2027. Both organizations have emphasized that the intervening period will be dedicated to a seamless migration of existing archives and manuscript submission workflows, ensuring minimal disruption for the global research community.

Chronology of Influence: 75 Years of Genetic Discovery

To understand the weight of this announcement, one must look at the history of the publications involved.

The Foundational Years (1948–1980)

Since its inception, AJHG has served as the primary repository for the human genetics community. During the mid-20th century, the journal was instrumental in publishing the foundational studies that moved genetics from a branch of theoretical biology to a clinical diagnostic tool. The articles within these early volumes document the rise of cytogenetics and the mapping of human genes to specific chromosomes.

The Genomic Revolution (1990–2010)

With the launch of the Human Genome Project, the journal’s influence expanded exponentially. AJHG became the go-to venue for landmark papers describing the sequencing of the human genome and the development of genome-wide association studies (GWAS). These papers transformed the scientific community’s understanding of complex diseases, providing the framework for modern personalized medicine.

The Modern Era and Open Access (2010–Present)

As the field matured, the need for faster, more accessible publication avenues grew. In response, ASHG launched HGG Advances to support the rapid dissemination of findings that required more flexible publication formats. This reflected a broader shift in the scientific publishing industry toward Open Access (OA) models, ensuring that research funded by public and private grants could be read by anyone, anywhere, without barriers.


Supporting Data: The Global Reach of ASHG Publications

The impact of ASHG’s journals is evidenced by their sustained high citation counts and their influence on global health policy.

Citation and Impact Metrics

AJHG consistently ranks in the top tier of genetics and heredity journals globally. According to recent impact factor metrics, the journal maintains a high Eigenfactor score, indicating that it is not only widely read but also highly influential in the citations of other major scientific journals.

Global Reach

ASHG’s readership spans continents, with significant concentrations of authors and reviewers in North America, Europe, and an rapidly growing contingent in Asia and the Pacific. The transition to OUP is specifically designed to capitalize on OUP’s robust international offices, which are expected to improve the accessibility of these journals in emerging scientific markets.

The Open Access Landscape

With HGG Advances, ASHG has successfully navigated the shift toward the Plan S model of research dissemination. Currently, the journal supports a wide range of article types—including negative results and large-scale replication studies—which are vital for scientific reproducibility. By partnering with OUP, ASHG expects to enhance the discoverability of these articles via OUP’s sophisticated digital platform.


Official Perspectives: A Unified Vision

The leadership at both ASHG and OUP have expressed high optimism regarding the long-term potential of this collaboration.

Susan A. Slaugenhaupt, PhD, ASHG President

"This partnership marks an exciting new chapter for ASHG’s journals and the communities they serve," stated Dr. Slaugenhaupt. "OUP’s deep publishing expertise, global reach, and strong support for society journals will help us expand the visibility and impact of the research we publish. Most importantly, it allows us to maintain the editorial independence and scientific standards that are central to ASHG’s mission."

Jennifer Paxton-Boyd, Publishing Director, Science at OUP

"Oxford University Press is delighted to collaborate with ASHG to publish its prestigious journals," said Paxton-Boyd. "We look forward to working with the Society and editors to broaden the reach of their high-quality research, support the Society’s mission, and serve the global human genetics and genomics community. Our goal is to ensure that the intellectual output of the ASHG membership reaches the widest possible audience, from clinical practitioners to academic researchers and policy influencers."


Implications: What This Means for the Scientific Community

The transition to OUP has several profound implications for the future of genetic research and scholarly communication.

1. Enhanced Digital Infrastructure

OUP provides a sophisticated, user-centric publishing platform that integrates with global indexing services. Researchers publishing in AJHG and HGG Advances can expect enhanced searchability, better data visualization tools, and more robust altmetrics to track the real-world impact of their work.

2. Stability for Society Journals

In an era where commercial publishers often consolidate and shift strategies, ASHG’s choice of OUP—a non-profit university press—signals a commitment to the "society-led" model of publishing. This provides a level of institutional stability that many independent journals lack, ensuring that the journals remain under the stewardship of the scientists they serve rather than being subject to the volatility of purely profit-driven entities.

3. Support for Early-Career Researchers

ASHG has long been a champion of the next generation of geneticists. Through this partnership, the Society plans to leverage OUP’s educational resources and outreach programs to better support early-career professionals in navigating the peer-review process, improving their scientific writing, and understanding the nuances of open-access licensing.

4. Policy Advocacy and Public Engagement

By strengthening the reach of its journals, ASHG is better positioned to influence public policy. As genetics becomes increasingly central to public health, the ability to disseminate accurate, peer-reviewed findings to policymakers and the general public is critical. The partnership with OUP will provide the infrastructure to better communicate complex genetic findings to broader audiences, including the development of lay-summaries and improved public-facing content.


Conclusion: A Future-Proof Strategy

The decision to partner with Oxford University Press is a calculated move to future-proof the ASHG’s intellectual assets. By combining ASHG’s rigorous, community-driven editorial oversight with OUP’s massive logistical and digital capabilities, the Society is ensuring that its journals remain at the pinnacle of human genetics research.

As the scientific community looks toward 2027, the focus remains on continuity. Authors and subscribers can expect a seamless transition that prioritizes the integrity of the record. In the coming months, ASHG plans to release further guidance for its members and contributors regarding manuscript submission transitions, reaffirming that while the publisher may change, the mission of the American Society of Human Genetics—to advance the science of human genomics for the benefit of all—remains steadfast.

For those interested in the latest updates, the Society encourages members to monitor the official ASHG website and attend the upcoming Annual Meeting, where leadership will host town halls to address specific questions regarding the new publishing partnership.

About the Author

Ali Ikhwan

Author

View All Posts

Post navigation

Previous: Beacon Therapeutics Poised for Breakthrough: Gene Therapy Laruparetigene Zovaparvovec Achieves Primary Endpoint in Pivotal XLRP Trial

Related Stories

a-new-era-in-genomic-medicine-casgevy-becomes-available-on-the-nhs
  • Genomics and Precision Medicine

A New Era in Genomic Medicine: Casgevy Becomes Available on the NHS

Nana Wu September 21, 2026
the-genetic-revolution-crafting-the-future-of-the-peanut-industry-1
  • Genomics and Precision Medicine

The Genetic Revolution: Crafting the Future of the Peanut Industry

Sagoh September 21, 2026
unlocking-the-non-coding-genome-how-a-single-insertion-rewrites-our-understanding-of-hereditary-spastic-paraplegia
  • Genomics and Precision Medicine

Unlocking the Non-Coding Genome: How a Single Insertion Rewrites Our Understanding of Hereditary Spastic Paraplegia

Asep Darmawan September 21, 2026

Recent Posts

  • A New Era for Genomic Science: ASHG Announces Strategic Publishing Partnership with Oxford University Press
  • Beacon Therapeutics Poised for Breakthrough: Gene Therapy Laruparetigene Zovaparvovec Achieves Primary Endpoint in Pivotal XLRP Trial
  • The Psychedelic Frontier: How Compass Pathways is Building on the "Spravato Blueprint" to Transform Mental Healthcare
  • The High Cost of Intermediation: Analyzing the Economics of Health Insurance and the Medicare-for-All Debate
  • Advancing the Frontier of Metastatic Breast Cancer Research: Advocacy, Innovation, and the Patient Voice

Recent Comments

No comments to show.

Archives

  • September 2026
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • September 2025
  • August 2025
  • July 2025

Categories

  • Breast Cancer Legislation and Policy
  • Breast Cancer Prevention and Lifestyle
  • Breast Cancer Surgery and Reconstruction
  • Chemotherapy and Targeted Therapy
  • Clinical Oncology Education
  • Clinical Radiology and Imaging
  • Genomics and Precision Medicine
  • Global Breast Cancer Awareness
  • Hormone Therapy and Endocrinology
  • Integrative Oncology and Holistic Care
  • Medical Research and Clinical Trials
  • Metastatic Breast Cancer Research
  • Patient Advocacy and Support
  • Psychosocial Support and Mental Health
  • Radiation Oncology
  • Survivorship and Post-Treatment
  • Treatment Innovations

You may have missed

a-new-era-for-genomic-science-ashg-announces-strategic-publishing-partnership-with-oxford-university-press-1
  • Genomics and Precision Medicine

A New Era for Genomic Science: ASHG Announces Strategic Publishing Partnership with Oxford University Press

Ali Ikhwan September 21, 2026
beacon-therapeutics-poised-for-breakthrough-gene-therapy-laruparetigene-zovaparvovec-achieves-primary-endpoint-in-pivotal-xlrp-trial
  • Medical Research and Clinical Trials

Beacon Therapeutics Poised for Breakthrough: Gene Therapy Laruparetigene Zovaparvovec Achieves Primary Endpoint in Pivotal XLRP Trial

Reynand Wu September 21, 2026
the-psychedelic-frontier-how-compass-pathways-is-building-on-the-spravato-blueprint-to-transform-mental-healthcare
  • Treatment Innovations

The Psychedelic Frontier: How Compass Pathways is Building on the "Spravato Blueprint" to Transform Mental Healthcare

Azzam Bilal Chamdy September 21, 2026
the-high-cost-of-intermediation-analyzing-the-economics-of-health-insurance-and-the-medicare-for-all-debate
  • Breast Cancer Legislation and Policy

The High Cost of Intermediation: Analyzing the Economics of Health Insurance and the Medicare-for-All Debate

Rifan Muazin September 21, 2026
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
  • Home
  • About Us
  • Contact Us
  • Cookies
  • Disclaimer
  • DMCA
  • Privacy Policy
  • TOS
Copyright © All rights reserved. | MoreNews by AF themes.